Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 180

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Omega-3 Fatty Acid Supplementation Decreases Liver Fat Content in Polycystic Ovary Syndrome: A Randomized Controlled Trial Employing Proton Magnetic Resonance Spectroscopy

Cussons, Andrea J., Watts, Gerald F., Mori, Trevor A., Stuckey, Bronwyn G. A.·2009·The Journal of Clinical Endocrinology & Metabolism

Abstract

CONTEXT: There is an association between nonalcoholic fatty liver disease (NAFLD) and the polycystic ovary syndrome (PCOS). Marine-derived omega-3 fatty acids have favorable effects on cardiovascular risk and could reduce liver fat in NAFLD. OBJECTIVE: The primary aim of this study was to examine the effects of omega-3 fatty acids on liver fat in PCOS. The secondary aim was to assess their effects on traditional cardiovascular risk factors. DESIGN AND SETTING: We conducted a randomized, crossover study at a tertiary cardiovascular research center. SUBJECTS: Twenty-five women with PCOS (mean age, 32.7 yr; mean body mass index, 34.8 kg/m(2)) participated in the study. INTERVENTION: We compared 4g/d of omega-3 fatty acids with placebo over 8 wk. MAIN OUTCOME MEASURES: The primary outcome measure was hepatic fat content quantified using proton magnetic resonance spectroscopy. Secondary outcome measures included fasting lipids and blood pressure. RESULTS: Omega-3 fatty acids significantly decreased liver fat content compared with placebo [10.2 (1.1) vs. 8.4 (0.9)%; P = 0.022]. There was also a reduction in triglycerides [1.19 (1.03-1.47) vs. 1.02 (0.93-1.18) mmol/liter; P = 0.002], systolic blood pressure [124.1 (12.1) vs. 122.3 (14.5) mm Hg; P = 0.018], and diastolic blood pressure [73.2 (8.4) vs. 69.7 (8.3) mm Hg; P = 0.005] with omega-3 fatty acids compared with placebo. Omega-3 fatty acids particularly decreased hepatic fat in women with hepatic steatosis, defined as liver fat percentage greater than 5% [18.2 (11.1) vs. 14.8 (9.3)%; P = 0.03]. CONCLUSIONS: Omega-3 fatty acid supplementation has a beneficial effect on liver fat content and other cardiovascular risk factors in women with PCOS, including those with hepatic steatosis. Whether this translates into a reduction in cardiometabolic events warrants further study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2009-0870

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 28

  1. Ehrmann, 2005, Polycystic ovary syndrome., N Engl J Med, 352, 1223, 10.1056/NEJMra041536 · DOI · Paper page
  2. Cussons, 2006, Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives., Atherosclerosis, 185, 227, 10.1016/j.atherosclerosis.2005.10.007 · DOI · Paper page
  3. Setji, 2006, Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome., J Clin Endocrinol Metab, 91, 1741, 10.1210/jc.2005-2774 · DOI · Paper page
  4. Schwimmer, 2005, Abnormal aminotransferase activity in women with polycystic ovary syndrome., Fertil Steril, 83, 494, 10.1016/j.fertnstert.2004.08.020 · DOI
  5. Cerda, 2007, Nonalcoholic fatty liver disease in women with polycystic ovary syndrome., J Hepatol, 47, 412, 10.1016/j.jhep.2007.04.012 · DOI · Paper page
  6. Gambarin-Gelwan, 2007, Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome., Clin Gastroenterol Hepatol, 5, 496, 10.1016/j.cgh.2006.10.010 · DOI · Paper page
  7. Brzozowska, 2009, An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome., J Gastroenterol Hepatol, 24, 243, 10.1111/j.1440-1746.2008.05740.x · DOI
  8. Chitturi, 2002, NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome., Hepatology, 35, 373, 10.1053/jhep.2002.30692 · DOI · Paper page
  9. Bellentani, 2008, Liver and heart: a new link?, J Hepatol, 49, 300, 10.1016/j.jhep.2008.05.003 · DOI
  10. Szczepaniak, 2005, Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population, Am J Physiol Endocrinol Metab, 288, E462, 10.1152/ajpendo.00064.2004 · DOI · Paper page
  11. Clark, 2002, Nonalcoholic fatty liver disease., Gastroenterology, 122, 1649, 10.1053/gast.2002.33573 · DOI · Paper page
  12. Gan, 2008, The trials and tribulations of the treatment of nonalcoholic fatty-liver disease., Curr Opin Lipidol, 19, 592, 10.1097/MOL.0b013e328317cc42 · DOI
  13. Alwayn, 2005, Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor., Transplantation, 79, 606, 10.1097/01.TP.0000150023.86487.44 · DOI
  14. Capanni, 2006, Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study., Aliment Pharmacol Ther, 23, 1143, 10.1111/j.1365-2036.2006.02885.x · DOI · Paper page
  15. Spadaro, 2008, Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease., Dig Liver Dis, 40, 194, 10.1016/j.dld.2007.10.003 · DOI · Paper page
  16. Zhu, 2008, Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia., World J Gastroenterol, 14, 6395, 10.3748/wjg.14.6395 · DOI · Paper page
  17. Mori, 2004, Omega-3 fatty acids and inflammation., Curr Atheroscler Rep, 6, 461, 10.1007/s11883-004-0087-5 · DOI · Paper page
  18. Mori, 2004, Effect of fish and fish oil-derived omega-3 fatty acids on lipid oxidation., Redox Rep, 9, 193, 10.1179/135100004225005200 · DOI
  19. Zawadski, 1992, Diagnostic criteria for polycystic ovary syndrome: towards a rational approach, In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic ovary syndrome. Boston: Blackwell;, 337
  20. 2004, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome., Fertil Steril, 81, 19, 10.1016/j.fertnstert.2003.10.004 · DOI · Paper page
  21. Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge., Clin Chem, 18, 499, 10.1093/clinchem/18.6.499 · DOI · Paper page
  22. Browning, 2004, Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity., Hepatology, 40, 1387, 10.1002/hep.20466 · DOI · Paper page
  23. Chan, 2006, Measurement of liver fat by magnetic resonance imaging: relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men., Diabetes Obes Metab, 8, 698, 10.1111/j.1463-1326.2005.00543.x · DOI
  24. Bradbury, 2004, Lipid metabolism in hepatic steatosis, Clin Liver Dis, 8, 639, 10.1016/j.cld.2004.04.005 · DOI
  25. Qi, 2008, Omega-3 fatty acid containing diets decrease plasma triglyceride concentrations in mice by reducing endogenous triglyceride synthesis and enhancing the blood clearance of triglyceride-rich particles., Clin Nutr, 27, 424, 10.1016/j.clnu.2008.02.001 · DOI
  26. Mori, 2006, Omega-3 fatty acids and hypertension in humans., Clin Exp Pharmacol Physiol, 33, 842, 10.1111/j.1440-1681.2006.04451.x · DOI
  27. Targher, 2008, Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?, Diabetologia, 51, 1947, 10.1007/s00125-008-1135-4 · DOI · Paper page
  28. Cussons, 28 2009, Dissociation of endothelial function and arterial stiffness in non-obese women with PCOS, Clin Endocrinol

Cited by

See all 180

Metadata

Authors
Cussons, A. J., Watts, G. F., Mori, T. A., & Stuckey, B. G. A.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2009-10-01
Volume
94
Issue
10
Pages
3842-3848
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2085908723
Cited by
180
References
9
FWCI
9.29
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Omega-3 Fatty Acid Supplementation Decreases Liver Fat Content in Polycystic Ovary Syndrome: A Randomized Controlled Trial Employing Proton Magnetic Resonance Spectroscopy. https://app.cochat.ai/papers/10.1210/jc.2009-0870
The paper
Cussons, A. J., Watts, G. F., Mori, T. A., & Stuckey, B. G. A. (2009). Omega-3 Fatty Acid Supplementation Decreases Liver Fat Content in Polycystic Ovary Syndrome: A Randomized Controlled Trial Employing Proton Magnetic Resonance Spectroscopy. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2009-0870

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.